Healx Doses First Patient in Trial of an AI-Discovered Drug Combination for Osteosarcoma
Source: Healx via BioSpace — 2026-07-22
Summary
AI-enabled biotech Healx dosed the first patient in a Phase 1/2 trial of HLX-4310, an oral combination of the HDAC inhibitor domatinostat and the mTOR inhibitor sirolimus, targeting metastatic recurrence and progression in sarcomas with a focus on osteosarcoma. The trial, run in adolescents and adults with relapsed or refractory disease, is advanced in partnership with the National Pediatric Cancer Foundation's Sunshine Project. Healx's AI discovery platform was used to identify and validate the combination, and this marks one of the first times an AI-discovered drug candidate has entered human dose-escalation in a pediatric-adjacent oncology population.
Key Takeaways
- HLX-4310 pairs domatinostat (a Class I-selective HDAC inhibitor) with sirolimus (an mTOR inhibitor) as an oral combination therapy.
- The target population is relapsed/refractory sarcoma in adolescents and adults, with a specific focus on osteosarcoma — a cancer with few approved options once it recurs after metastasis.
- Healx's AI platform drove target and combination identification, paired with rapid iterative lab testing and translational validation before advancing to the clinic.
- The trial runs in collaboration with the National Pediatric Cancer Foundation's Sunshine Project, a flagship pediatric cancer research initiative.
- This is described as one of the first AI-discovered drug candidates to reach first-in-human dose-escalation in a pediatric-adjacent oncology setting — a milestone for whether AI-driven discovery platforms can actually get a candidate into patients, not just identify it computationally.